Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Sprenger, Thilo ^a   Rothe, Hilka ^a   Jung, Klaus ^a   Christiansen, Hans ^a   Conradi, Lena C ^a   Ghadimi, B Michael ^a   Becker, Heinz ^a   Liersch, Torsten ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; RECTUM CARCINOMA; RECTUM SURGERY; RISK; RISK STRATIFICATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RECTUM TUMOR; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950678271     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-27     Document Type: Article

References (37)

1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence?. Br J Surg 1982, 69:613-6. 10.1002/bjs.1800691019, 6751457.
2. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993, 341:457-60. 10.1016/0140-6736(93)90207-W, 8094488.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, Velde CJ, . Dutch Colorectal Cancer Group Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-46. 10.1056/NEJMoa010580, 11547717, Dutch Colorectal Cancer Group.
4. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997, 336:980-7. 10.1056/NEJM199704033361402, 9091798.
5. Lavery IC, Fazio VW, Lopez-Kostner F. Radiotherapy for rectal cancer. N Engl J Med 1997, 337:346-7. author reply 347-8, 10.1056/NEJM199707313370514, 9235500.
6. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, . German Rectal Cancer Study Group Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-40. 10.1056/NEJMoa040694, 15496622, German Rectal Cancer Study Group.
7. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C. [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008, 46:799-840. 10.1055/s-2008-1027726, 18759205.
8. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002, 45:895-903. 10.1007/s10350-004-6325-7, 12130878.
9. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, Guillemin F, Bey P. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys 1998, 42:935-41.
10. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-96. 10.1200/JCO.2005.02.1329, 16246976.
11. Miyoshi M, Ueno H, Hashiguchi Y, Mochizuki H, Talbot IC. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg 2006, 243:492-8. 10.1097/01.sla.0000205627.05769.08, 1448973, 16552200.
12. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy?. Dis Colon Rectum 1999, 42:167-73. 10.1007/BF02237122, 10211491.
13. Steel MC, Woods R, Mackay JM, Chen F. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg 2002, 72:483-7. 10.1046/j.1445-2197.2002.02457.x, 12123507.
14. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003, 21:19-22. 10.1002/ssu.10017, 12923912.
15. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G, . European Organisation for Research and Treatment of Cancer Radiation Oncology Group Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-86. 10.1200/JCO.2007.11.9685, 17906203, European Organisation for Research and Treatment of Cancer Radiation Oncology Group.
16. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-5. 10.1200/JCO.2006.06.7629, 17008704.
17. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12:19-23. 10.1007/s003840050072, 9112145.
18. Nagtegaal ID, Velde CJ, Worp E, Kapiteijn E, Quirke P, van Krieken JH, . Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002, 20:1729-34. 10.1200/JCO.2002.07.010, 11919228, Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group.
19. Greene FL, Brierley J, O'Sullivan B, Sobin LH, Wittekind C, . International Union Against Cancer and American Joint Committee on Cancer On the use and abuse of X in the TNM classification. Cancer 2005, 103:647-9. 10.1002/cncr.20808, 15612025, International Union Against Cancer and American Joint Committee on Cancer.
20. UICC TNM Supplement 2001. A commentary on uniform use 2001, John Wiley & Sons, New York, Wittekind Ch, Henson DE, Hutter RVP, Sobin LH, 2, UICC.
21. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25:110-7. 10.1200/JCO.2006.08.3675, 17194912.
22. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, Brule AJ, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007, 13:6617-23. 10.1158/1078-0432.CCR-07-1197, 18006762.
23. Merkel S, Mansmann U, Papadopoulos T, Wittekind C, Hohenberger W, Hermanek P. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer 2001, 92:2754-9. 10.1002/1097-0142(20011201)92:11<2754::AID-CNCR10083>3.0.CO;2-4, 11753948.
24. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324:709-15.
25. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009, 115:5432-40. 10.1002/cncr.24622, 19673001.
26. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY. Pathologic Nodal Classification Is the Most Discriminating Prognostic Factor for Disease-Free Survival in Rectal Cancer Patients Treated with Preoperative Chemoradiotherapy and Curative Resection. Int J Radiat Oncol Biol Phys 2009,
27. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008, 113:57-64. 10.1002/cncr.23516, 18442099.
28. Baxter NN, Morris AM, Rothenberger DA, Tepper JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys 2005, 61:426-31.
29. Habr-Gama A, Perez RO, Proscurshim I, Rawet V, Pereira DD, Sousa AH, Kiss D, Cecconello I. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean?. Dis Colon Rectum 2008, 51:277-83. 10.1007/s10350-007-9148-5, 18183463.
30. Wichmann MW, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, Angele MK, Schildberg FW. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002, 137:206-10. 10.1001/archsurg.137.2.206, 11822961.
31. Wijesuriya RE, Deen KI, Hewavisenthi J, Balawardana J, Perera M. Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly. Surg Today 2005, 35:442-5. 10.1007/s00595-004-2956-5, 15912290.
32. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, Cummings B, Gunderson L, Macdonald JS, Mayer RJ. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19:157-63.
33. Morris EJ, Maughan NJ, Forman D, Quirke P. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. J Clin Oncol 2007, 25:2573-9. 10.1200/JCO.2007.11.0445, 17577036.
34. Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, Schrag D. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. J Surg Oncol 2009, 100:525-8. 10.1002/jso.21373, 19697351.
35. Kim YW, Kim NK, Min BS, Lee KY, Sohn SK, Cho CH. The influence of the number of retrieved lymph nodes on staging and survival in patients with stage II and III rectal cancer undergoing tumor-specific mesorectal excision. Ann Surg 2009, 249:965-72. 10.1097/SLA.0b013e3181a6cc25, 19474683.
36. Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006, 49:1284-92. 10.1007/s10350-006-0570-x, 16758130.
37. Huh JW, Kim HR. Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: Is it essential for patients with ypT0-2N0?. J Surg Oncol 2009, 100:387-391. 10.1002/jso.21342, 19582821.